News

Eurofins Scientific (EUFI.PA), a global leader in bioanalytical testing, announces the closing of its acquisition of Ascend Clinical, LLC (“Ascend”), the largest independent laboratory for...

With Illumina Connected Analytics, Eurofins Viracor can now analyze complex data sets, freeing them up to make greater discoveries Around the world, sequencing laboratories are experiencing an increase in the demand for clinical next-generation sequencing (NGS). But with that demand comes the possibility of a bioinformatics bottleneck. No one understands this more than Eurofins ...

Eurofins Viracor ExPeCT™ CAR-T multiplexed quantitative real-time PCR (qPCR) assay provides a powerful diagnostic tool to monitor and optimize CAR-T therapy...

Eurofins Viracor, a leader in infectious disease and immunology testing, today celebrated the opening of its expansive new laboratory in Lenexa, KS. The 110,000 square foot, state-of-the-art facility will be home to 450 employees, comprised of 215 current employees and...

Eurofins Viracor, a leader in infectious disease and immunology testing, launches a functional T Cell test to measure CD4 and CD8 Epstein-Barr virus-specific T cell immune response. The test joins the innovative inSIGHT diagnostic portfolio of virus-specific cell mediated immunity tests offered by Viracor. EBV is a common risk factor for post-transplant lymphoproliferative diso ...

Innovation and process improvement have been two crucial success factors for Kansas-based Eurofins Viracor. The company is passionate about providing timely, actionable test results, never losing sight of the connection between the testing and the patients...

Eurofins Viracor, a leader in infectious disease, immunology, and allergy testing, announced today that the Third Circuit of the Federal Court of Appeals affirmed the U.S. District Court for the District of Delaware’s entry of judgment in Eurofins Viracor’s favor that the patent asserted in CareDx’s patent infringement case against Eurofins Viracor is invalid.  Eurofins Viracor ...

Blood and urine-based cell-free DNA detection methods will provide healthcare practitioners with highly accurate, non-invasive tools to identify and monitor for infection, rejection, and severity of organ damage in transplant and COVID-19 patients. Eurofins Viracor, LLC, a leader in testing for infectious disease, immunology, and allergy, announced today that it has entered int ...

OmniGraf™ – the first and only rejection assay on the market that combines the power of gene expression profiling (TruGraf^®) and donor-derived cell-free DNA (Viracor TRAC^®) in one non-invasive, easy-to-draw test. OmniGraf offers the highest positive predictive value (PPV) and negative predictive value (NPV) of any kidney test available, empowering clinicians and patients to make the best possible treatment decisions with the goal of improving long-term graft outcomes.

NEW YORK – While vaccines for SARS-CoV-2 have rolled out at home and abroad, there is still uncertainty about their long-term effectiveness against the virus, and questions linger about whether a booster shot will be necessary and how often individuals will need to get vaccinated to remain protected against the virus. Against this backdrop Eurofins Viracor has developed a test ...